AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug PressureZacks Investment Research • 08/05/26
AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class Action Investigation into Exposure of Patient Health InformationGlobeNewsWire • 08/05/26
Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/04/26
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity TreatmentWSJ • 08/04/26
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter SmashInvestors Business Daily • 08/04/26
What Analyst Projections for Key Metrics Reveal About Amgen (AMGN) Q2 EarningsZacks Investment Research • 07/30/26
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your PatientsThe Motley Fool • 07/29/26
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?24/7 Wall Street • 07/17/26